JACS Highlights March 2025
March 5, 2025
The following articles appear in the March 2025 issues of the Journal of the American College of Surgeons. A complimentary online subscription to JACS is a benefit of ACS membership. See more articles on the JACS website.
Role of Minimally Invasive Reoperation for Postoperatively Diagnosed T2 Gallbladder Cancer: Multicenter Retrospective Cohort Study
Yeshong Park, MD, Sae Byeol Choi, MD, PhD, Boram Lee, MD, and colleagues
Minimally invasive reoperation for postoperatively diagnosed gallbladder cancer can be technically challenging. The authors of this study evaluated 148 patients who underwent reoperation for postoperatively diagnosed T2 gallbladder cancer. Laparoscopic reoperation showed favorable postoperative outcomes and noninferior oncologic outcomes when compared with open operation. Read more.
Validation of Artificial Intelligence-Based POTTER Calculator in Emergency General Surgery Patients Undergoing Laparotomy: Prospective, Bi-Institutional Study
Vahe S. Panossian, MD, Dias Argandykov, MD, Suzanne C. Arnold, MD, and colleagues
This study prospectively validates the POTTER artificial intelligence risk calculator in emergency laparotomy patients. POTTER accurately predicts mortality and postoperative complications. The superior accuracy, user-friendliness, and interpretability of POTTER make it a useful bedside tool for preoperative counseling. Read more.
Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer: The LUMINA Study
Marta Antoniv, MD; Andrei Nikiforchin, MD; Naomi M. Sell, MD, MHS; and colleagues
Alison Laws, MD, MPH, FRCSC, Muriel Brackstone, MD, MSc, PhD, FRCSC, and May Lynn Quan, MD, MSc, FRCSC
The authors of this paper reviewed the LUMINA Trial and found that, while the LUMINA study was rigorously designed and executed, there are significant pragmatic limitations to the proposed approach using this protocol. The authors of the JACS study advocate that there is no “one-size-fits-all” approach to early estrogen receptor positive breast cancer. Read more.
